It increases breast cancer cell migration, proliferation, and tumor development, activates estrogen-responsive genes in endocrine-resistant tumors and associates with unfavorable biomarkers in breast cancer, suggesting ERRα as novel target for therapy of breast cancer (Ariazi et al. 2002; May 2014). The gene discussed is ESRRA; the disease is neoplasm.